Janssen Biotech Inc.

03/18/2024 | Press release | Distributed by Public on 03/18/2024 07:17

RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer